R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Go back to R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease| CARLYLE GP (NASDAQ: CG) | Delayed: 44.57 -0.23 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.80 | 52 Week High | $18.40 | |||
| Open | $44.76 | 52 Week Low | $11.25 | |||
| Day High | $45.27 | P/E | 66.52 | |||
| Day Low | $43.98 | EPS | $0.67 | |||
| Volume | 1,887,757 | |||||
| DaVita Inc. (NYSE: DVA) | Delayed: 209.68 +1.77 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $207.91 | 52 Week High | $78.77 | |||
| Open | $209.07 | 52 Week Low | $55.00 | |||
| Day High | $215.33 | P/E | 72.55 | |||
| Day Low | $208.62 | EPS | $2.89 | |||
| Volume | 783,123 | |||||
